DIPARTIMENTO DI SCIENZE BIOMEDICHE

Pubblicazioni

PROF. TULLIO GIRALDI, FIORA BARTOLI, GIULIANA DECORTI, DR. LUIGI CANDUSSIO

Fiora Bartoli, Giuliana Decorti, Luigi Candussio, Luciano Baldini      

  1. Crivellato E., Candussio L., Decorti G., Bartoli Klugmann F., Mallardi F., Baldini L.: Stimulation of rat peritoneal mast cells induces the phagocytosis of adriamycin by rat peritoneal macrophages. Biotechnic-Histochem. 73: 82-91, 1998.

  2. Decorti G., Peloso I., Favarin D., Bartoli Klugmann F., Candussio L., Crivellato E., Mallardi F., Baldini L.: Transport of adriamycin in the LLC-PK1 kidney epithelial cell line. J. Pharmacol. Exp. Ther. 286: 525-530, 1998.

  3. Candussio L., Decorti G., Crivellato E., Rosati A.M., Traversa U., Bartoli Klugmann F.: Transport of Doxorubicin in mast cell granules and effect of the calcium antagonist verapamil. Anticancer Res. 19: 1101-1108, 1999.

  4. Crivellato E., Candussio L., Decorti G., Bartoli Klugmann F., Mallardi F.: Adriamycin induces exocytosis in rat and beige mouse peritoneal mast cells: an ultrastructural, morphometric and biochemical study. J. Submicrosc. Cytol. Pathol. 31: 279-286, 1999.

  5. Decorti G., Malusà N., Furlan G., Candussio L., Bartoli Klugmann F.: Endocytosis of gentamicin in a proximal tubular cell line. Life Sci. 65: 1115-1124, 1999.

  6. Crivellato E., Candussio L., Rosati A.M., Decorti G., Bartoli Klugmann F., Mallardi F.: Kinetics of doxorubicin handling in LLC-PK1 kidney epithelial cell line is mediated by both vescicle formation and P-glycoprotein drug transport. Histochem. J. 31: 635-643, 1999.

  7. Crivellato E., Candussio L., Decorti G., Bartoli Klugmann F., Mallardi F.: Effect of low temperature on mast cell exocytosis. Early cytoplasmic vesicle formation and the role of cytoskeleton. J. Submicrosc. Cytol. Pathol. 31:477-485, 1999.

  8. Decorti G., Malusà N., Furlan G., Candussio L., Bartoli Klugmann F.: Endocytosis of gentamicin in a proximal tubular cell line. Life Sci. 65: 1115-1124, 1999.

  9. Crivellato E., Candussio L., Rosati A.M., Decorti G., Bartoli Klugmann F., Mallardi F.: Kinetics of doxorubicin handling in LLC-PK1 kidney epithelial cell line is mediated by both vescicle formation and P-glycoprotein drug transport. Histochem. J. 31: 635-643, 1999.

  10. Candussio L., Crivellato E.,  Decorti G., Bartoli Klugmann F., Mallardi F.: Effect of low temperature on mast cell exocytosis. Early cytoplasmic vesicle formation and the role of cytoskeleton. J. Submicrosc. Cytol. Pathol. 31:477-485, 1999.

  11. Crivellato E, Donini A, Baccarani U, Lavaroni S, Candussio L,Degrassi A, Bresaola F. Efficiency of doxorubicin handling by isolated hepatocytes is a valuable indicator for restored cell funcion. The Histochemical J. 32,535-543, 2000

  12. Decorti G., Bartoli Klugmann F., Crivellato E., Malusà N., Furlan G., Candussio L., Giraldi T.: Biochemical and microscopic evidence for the internalization of drug-containing mast cell granules by macrophages and smooth muscle cells. Toxicol. Appl. Pharmacol. 169: 269-275, 2000.

  13. Rosati A., Decorti G., Bartoli Klugmann F., Candussio L., Granzotto M., Melato M., Giraldi T.: Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart. Anticancer Res. 20: 3403-3410, 2000.    

  14. Decorti G., Rosati A., Candussio L., Giraldi T., Bartoli Klugmann F.: Characterization of multidrug transporters in a normal renal tubular cell line resistant to doxorubicin. Biochem. Pharmacol. 61: 61-66, 2001.

  15. Ribatti D, Crivellato E, Candussio L, Nico B, Vacca A, Dammacco F. Mast cells and their secretori granules are angiogenic in the chick embryo chorioallantoic membrane.Clin.Exp. Alergy 31: 602-608, 2001.

  16. Granzotto M., Rapozzi V., Decorti G., Giraldi T.: Effects of melatonin on doxorubicin cytotoxicity in sensitive and pleiotropically resistant tumor cells. J. Pineal Res. 31: 206-213, 2001.

  17. Candussio L., Crivellato E., Rosati A.M., Bartoli Klugmann F., Granzotto M., Giraldi T., Decorti G.: Expression and function of the P-glycoprotein and the Multidrug Resistance-related Protein efflux pumps in rat and beige mouse peritoneal mast cells. Histochem. J. 33: 259-266, 2001.

  18. Crivellato E., Candussio L., Rosati A.M., Bartoli Klugmann F., Maliardi F., Decorti G.: The fluorescent probe Bodipy-FL-Verapamil is a substrate for both P-glycoprotein and Multidrug resistance-related Protein (MRP)-1. J. Histochem. Cytochem. 50: 731-734, 2002.

  19. Candussio L., Decorti G., Crivellato E., Granzotto M., Rosati A., Giraldi T., Bartoli F.: Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin. Life Sci. 71: 3109-3119, 2002.

  20. Rosati A., Maniori S., Decorti G., Candussio L., Giraldi T., Bartoli Klugmann F., "Physiological regulation of P-glycoprotein, MRP1,MRP2, and cytochrome P450 3A2 during rat ontogeny". Development growth and differentiation, 2003, Vol. 45, n. 4, pp. 377-387.

  21. Magnarin M., Morelli M., Rosati A., Bartoli Klugmann F., Candussio L., Giraldi T., Decorti G., "Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK(1) cells.". European journal of pharmacology, 2004, Vol. 483, n. 1, pp. 19-28.

 

 Tullio Giraldi

 

  1. Bone marrow toxicity and antitumor action of adriamycin in relation to the antioxidant effects of melatonin. Rapozzi,V, Perissin,L., Zorzet,S., Comelli,M., Mavelli,I., Sentjurc,M., Pregelj,A., Schara,M., Giraldi,T. Radiat. Oncol. 32: 95-102 (1998).

  2. Restraint stress reduces the antitumor efficacy of cyclophosphamide in tumor-bearing mice. Zorzet, S., Perissin, L., Rapozzi, V. and Giraldi, T. Brain, Behavior and Immunity 12: 23-33 (1998). 

  3. Seasonal effects of rotational stress on Lewis lung carcinoma metastasis and T-lymphocyte subsets in mice. Perissin, L., Zorzet, S., Rapozzi, V., Carignola R., Angeli A. and Giraldi, T., Life Sciences 63: 711-719 (1998).

  4. Melatonin decreases bone marrow and lymphatic toxicity of Adriamycin in mice bearing TLX5 lymphoma. Rapozzi, V., Zorzet, S., Comelli, M., Mavelli, I., Perissin, L. and Giraldi, T. Life Sciences 63: 1701-1713 (1998).

  5. Melatonin administration in tumor bearing mice (intact or pinealectomized) in relation to stress, zinc, thymulin and IL-2. Mocchegiani, E., Perissin, L,. Santarelli, L., Tibaldi, A., Zorzet, S., Rapozzi, V., Giacconi, R., Bulian, D. and Giraldi, T. International Journal of Immunopharmacology 21: 27-46 (1999).

  6. Melatonin and oxidative damage in mice liver induced by the prooxidant antitumor drug, adriamycin. Rapozzi, V., Comelli, M., Mavelli, I., Sentjurc, M., Schara, M., Perissin, L. and Giraldi, T. In vivo 13: 45-50 (1999).

  7. Nuovi elementi di farmacologia delle terapie antimetastatiche. Tullio Giraldi In: Invasione e metastasi (G. Bevilacqua, R. Giavazzi, P.L. Lollini Eds.) Pacini Editore, Pisa 1999, pp 325-340.

  8. Physician's attitudes to and problems with truth-telling to cancer patients. Grassi, L., Giraldi, T., Messina, E.G., Magnani, K., Valle, E. and Cartei, G. Support Care Cancer 8: 40-45 (2000).

  9. Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart. Rosati A, Decorti G, Klugmann FB, Candussio L, Granzotto M, Melato M and Giraldi T. Anticancer Res. 20: 3403-3410 (2000).

  10. Biochemical and Microscopic Evidence for the Internalization of Drug-Containing Mast Cell Granules by Macrophages and Smooth Muscle Cells. Decorti G., Bartoli Klugmann F., Crivellato E., Malusa N., Furlan G., Candussio L. and Giraldi T. Toxicology and Applied Pharmacology 169: 269-275 (2000).

  11. Stress and chemotherapy: combined effects on tumor progression and immunity in animal models. Giraldi, T., Zorzet, S., Perissin, L. and Rapozzi, V. Annals New York Academy of Sciences, 917:549-59 (2000).

  12. Characterization of multidrug transporters in a normal renal tubular cell line resistant to doxorubicin. Multidrug transporters in the LLC-PK(1) cell line and its resistant counterpart. Decorti G., Rosati A., Candussio L., Giraldi T. and Bartoli Klugmann F. Biochemical Pharmacology 61: 61-66 (2001).  

  13. Effects of melatonin on doxorubicin cytotoxicity in sensitive and pleiotropically resistant tumor cells. Granzotto M., Rapozzi V., Decorti G., Giraldi T:  J. Pineal Res. 31: 206-213, 2001.

  14. Expression and function of the P-glycoprotein and the Multidrug Resistance-related Protein efflux pumps in rat and beige mouse peritoneal mast cells. Candussio L., Crivellato E., Rosati A.M., Bartoli Klugmann F., Granzotto M., Giraldi T., Decorti G.  Histochem. J. 33: 259-266, 2001.

  15. Zorzet S., Perissin L., Rapozzi V., Giraldi T., "Seasonal dependency of the effects of rotational stress and cyclophosphamide in mice bearing Lewis lung carcinoma.". Brain behavior and immunity, 2002, Vol. 16, n. 4, pp. 368-382.

  16. Giraldi T., "Stress, metastasi e curabilità dei tumori". In Psiconcologia, Bellani M., Morasso G., Amadori D., Orrù W., Grassi L., Casali P., Bruzzi P. (a cura di), Milano: Masson Ed, 2002, pp. 97-108.

  17. Candussio L., Decorti G., Crivellato E., Granzotto M., Rosati A., Giraldi T., Bartoli Klugmann F., "Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin.". Life sciences, 2002, Vol. 71, n. 26, pp. 3109-3119.

  18. Seasonal dependency of the effects of rotational stress and cyclophosphamide in mice bearing Lewis lung carcinoma.S. Zorzet, L. Perissin, V. Rapozzi, T. Giraldi.Brain Behav. Immun. 16, 368-382 (2002).

  19. Rosati A., Maniori S., Decorti G., Candussio L., Giraldi T., Bartoli Klugmann F., "Physiological regulation of P-glycoprotein, MRP1,MRP2, and cytochrome P450 3A2 during rat ontogeny". Development growth and differentiation, 2003, Vol. 45, n. 4, pp. 377-387.

  20. Magnarin M., Morelli M., Rosati A., Bartoli Klugmann F., Candussio L., Giraldi T., Decorti G., "Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK(1) cells.". European journal of pharmacology, 2004, Vol. 483, n. 1, pp. 19-28.

PROF.LUISA de ANGELIS

 

  1. Aguglia E, de Angelis L, Allegranti I. Disturbi dell' invecchiamento. Principi generali di psicofarmacologia geriatrica. In: Cassano GB, Pancheri P (eds), Trattato Italiano di Psichiatria, vol II, Milano, Masson, 1999, 2607 – 2612.
  2. de Angelis, L., Furlan, C.: The anxiolytic-like properties of two selective MAOIs, moclobemide and selegiline, in a standard and an enhanced light/dark aversion test. Pharmacol. Biochem. Behav., 65: 649-653, 2000.
  3. de Angelis. L.: Farmacodinamica e farmacocinetica dei farmaci psicoattivi nell'invecchiamento cerebrale e nella demenza degenerativa primaria. In: Pancheri P, Ravizza L (eds): Demenza Degenerativa Primaria e Disturbi Depressivi. Pisa, Pacini, 2000, 245-280.
  4. de Angelis, L. (section reviewer). Sharpe M., Iarvis B., Goa Kl.: Telmisartan. A review of its use in hypertension. Drugs 6: 1501 – 1529, 2001
  5. de Angelis. L.: 5-HT2A antagonists in psychiatric disorders. Curr. Opin. Inv. Drugs 3:106-112, 2002
  6. Bernobich, L., de Angelis, L. Lerin, C., Bellini, G.: Role of angiotensin system in cardiac glucose homeostasis: therapeutic implications. Drugs 62:1295-1314, 2002
  7. Bizzarini E. and de Angelis, L.: Is the use of oral creatine supplementation safe? J. Sports Med. Phys. Fitness (in press)
  8. Padovan Lang, A. and de Angelis, L.: Experimental anxiety and antiepileptics: the effect of valproate and vigabatrin in the mirrored chamber test. Methods Find Exp Clin Pharmacol. 2003 May;25(4):265-71.
     

   

PROF. ARIELLA FURLANI, GIANNI SAVA, UGO TRAVERSA DR. VITO SCARCIA, CHIARA FLORIO, SONIA ZORZET, SABRINA PACOR

Chiara Florio

  1. "Adenosine A1 recetors modulate anxiety in CD1 mice". In coll. con Florio C., Prezioso A., Papaioannou A.. Psychopharmacology 1998. 136. 311-319.

  2. "Adenosine and its receptors". In coll. con Florio C., Frausin F. Period.Biol. 1997. 4. 477-488.

  3. Florio C, Prezioso A, Papaioannou A, Vertua R. Adenosine A1 receptors modulate anxiety in D1 mice.Psychopharmacology, 136: 311-319 (1998)

  4. Frausin F, Florio C, Vertua R, Gaion RM. Cyclic AMP extrusion and ecto-phosphodiesterase activity in PC12 cells. Drug Develop. Res. 43: 22 (1998)

  5. Florio C, Frausin F, Vertua R, Gaion RM.Stimulation of adenylyl cyclase activity by forskolin in PC12 cells is highly dependent on endogenous adenosine. Drug Develop. Res. 43: 13 (1998)

  6. Frausin F, Florio C, Vertua R, Gaion RM.Endogenous adenosine facilitates adenylyl cyclase activation in PC12 cells.Naunyn-Schmiedeberg’s Arch Pharmacol 358: R132 (1998)

  7. Florio C, Frausin F, Vertua R, Gaion RM.Dipyridamole affects cyclic AMP accumulation in PC12 cells through multiple mechanismsFund. Clin. Pharmacol 13: 269 (1999)

  8. Florio C, Frausin F, Vertua R, Gaion RMInvolvement of P1 receptors in the effect of forskolin on cyclic AMP accumulation and export in PC12 cells.Biochem. Pharmacol. 57: 355-364 (1999)

  9. Florio C, Frausin F, Vertua R, Gaion RM.Amplification of the cyclic AMP response to forskolin in pheochromocytoma PC12 cells through adenosine A2A purinoceptors.1999

  10. Castellano S, Zorzin L, Florio C, Frausin F, Stefancich G. Synthesis of 11-aryl-5H-imidazo[2,1-c][1,4]benzodiazepines and their benzodiazepine and A1 adenosine binding activity. Il Farmaco 56, 771-778 (2001).

 Ariella Furlani, Vito Scarcia

  1. Tusek-Bozic, Furlani, Scarcia, DeClercq, Balzarini.Spectroscopic and biological properties of palladium(II) complexes of ethyl 2-quinolylmethylphosphonate.Journal pf Inorganic Biochemistry, 72, 201 (1998)

  2. Bergamo, Gagliardi, Scarcia, Furlani, Alessio, Mestroni, Sava.In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.Journal of Pharmacology and Experimental Therapeutics, 289, 559 (1999)

  3. Scarcia, Furlani, Fregona, Faraglia, Sitran.Palladium and platinum dithiocarbamato complexes containing mono- and diamines.Polyhedron, 18, 2827 (1999) 

  4. Tusek-Bozic Lj, Komac M, Curic M, Lycka A, D’Alpaos M, Scarcia V, Furlani A.Fivemembered [C,N] and [N.O] metallocyclic complex of palladium (II) with monoalkyl [a-(4-benzeneazoanilino)-N-benzyl]phosphonates: sunthesis, characterization and antitumor activity, Polyhedron, 19, 937-948 (2000)

  5. Alvarez Boo P, Casas J S,Castellano E E, Couce M D, Freijanes E, Furlani A, Russo U, Scarcia V, Sordo J, Varala M. Synthesis, characterization and cytotoxic activity of complexes of diorganotin(IV) dihalides with mepirizole;Appl.Organomet.Chem. 15, 75-81 (2001)

  6. Sava G, Bergamo A, Zorzet S, Gava B, Casarsa C, Cocchietto M, Furlani A, Scarcia V, Serli B, Iengo E, Alessio E, Mestroni G. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A. Eur. J. Cancer, 38: 427-435, 2002.

  7. Frausin F, Cocchietto M, Bergamo A, Scarcia V, Furlani A, Sava G. Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells. Cancer Chemother. Pharmacol., 50: 405-411, 2002.

  8. Tusek - Bozic L., Frausin F., Scarcia V., Furlani A., “Synthesis, characterization and antitumor activity of platinum(II) complexes with diethyl and monoethyl 2-quinolylmethylphosphonates”. Journal of inorganic biochemistry, 2003, Vol. 95, n. 4, pp. 259-269.

  Gianni Sava, Sabrina Pacor, Sonia Zorzet

  1. Capozzi I, Clerici K, Cocchietto M, Salerno G, Bergamo A, Sava G.Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulphoxide-ruthenium compunds and cisplatin detected by flow cytometry.Chemico-Biological Interactions, 113, 51 (1998)

  2. Mestroni G, Alessio E, Sessanta O Santi A, Geremia S, Bergamo A, Sava G, Boccarelli A, Schettino A, Coluccia M..Rhodium(III) analogues of antitumour-active ruthenium(III) compounds: the crystal structure of [ImH][trans-RhCl4(Im)2] (Im= imidazole).Inorganica Chimica Acta, 273, 62 (1998).

  3. Sava G, Capozzi I, Clerici K, Gagliardi R, Alessio E, Mestroni G.Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex.Clinical & Experimental Metastasis, 16, 371 (1998)

  4. Sava G, Gagliardi R, Cocchietto M, Clerici K, Capozzi I, Marrella M, Alessio E, Mestroni G, Milanino R.Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice.Pathology & Oncology Research, 4, 30 (1998)

  5. Pacor S, Gagliardi R, Magnarin M, Carotenuto Me, Zabucchi G, Sava G.Reduction of growth ability and tumorigenicity of IL-4 transfected TS/A adenocarcinoma line is mediated by increased adhesion molecule expression..Haematologica, 83, 22 (1998)

  6. Sava G., Clerici  K, Capozzi I, Cocchietto M, Gagliardi R, Alessio E, Mestroni G, Perbellini A.Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumours.Anti Cancer Drugs, 10, 129.1999

  7. Bergamo A, Gagliardi R, Scarcia V, Furlani A, Alessio E, Mestroni G, Sava G.In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. J. Pharmacol. Expl. Ther., 289, 559 1999

  8. Sava G, Gagliardi R, Bergamo A, Alessio E, Mestroni G.Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine.Anticancer Res., 19, 969 1999

  9. Sava G, Bergamo G.Drug control of solid tumour metastases: a critical view.Anticancer Res., 19, 1117 1999

  10. Sava G, Alessio E, Bergamo A, Mestroni G.Sulphoxide ruthenium complexes: non toxic tools for the selective treatment of solid tumour metastases.In: "Topics in Biological Inorganic Chemistry-Metallopharmaceuticals I" (MJ Clarke, PJ Sadler Eds.), Springer, Berlin, 143 1999

  11. Pacor S, Gagliardi R , Spessotto P, Zabucchi G, Sava G.Paracrine effects of IL-4 transfection on TS/A adenocarcinoma cells mediate reduced in vivo growth. Pathol. Oncol. Res., 5, 110 1999

  12. Pacor S, Gagliardi R, Di Daniel, Vadori, Sava G.In vitro down regulation of ICAM-1 and E-cadherin and in vivo reduction of lung metastases of TS/A adenocarcinoma by a lysozyme derivative.Int. J. Mol. Med., 4, 369 1999.

  13. Zorzet S., Bergamo A., Cocchietto M., Alessio E., Iengo E., Sava G., "Lack of in vitro cytotoxicity, associated to increased G2-M cell fraction and inhibition of matrigel invasion, may predict in vivo-selective antimetastasis activity of ruthenium complexes". Journal of pharmacology and experimental therapeutics, 2000, Vol. 295, n. 3, pp. 927-933.

  14. Sava G., Cocchietto M., "Blood levels of ruthenium following repeated treatments with the antimetastatic compound NAMI-A in healthy Beagle dogs". In Vivo, 2000, Vol. 14, pp. 741-745.

  15. Bergamo A., Zorzet S., Gava B., Sorc A., Alessio E., Iengo E., Sava G., "Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells". Anticancer drug, 2000, Vol. 11, n. 8, pp. 665-672.

  16. Sava G., Bergamo A., "Ruthenium-based compounds and tumour growth control (review)". International journal of oncology, 2000, Vol. 17, n. 2, pp. 353-365.

  17. Pacor S., Magnarin M., Carotenuto M. E., Spessotto P., Zabucchi G., Sava G., "In vitro growth of TS/A adenocarcinoma and of the gene transfected TS/A-IL4 line on biological substrates". Anticancer research, 2000, Vol. 20, n. 1A, pp. 191-196.

  18. Magnarin M., Bergamo A., Carotenuto M. E., Zorzet S., Sava G., "Increase of tumor infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A". Anticancer research, 2000, Vol. 20, n. 5A, pp. 2939-2944.

  19. Cocchietto M., Sava G., "Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice". Pharmacology and toxicology, 2000, Vol. 87, n. 5, pp. 193-197.

  20. Cocchietto M., Alessio E., Mestroni G., Sava G., "Fate of the antimetastatic ruthenium complex ImH[trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice". Anticancer research, 2000, Vol. 20, pp. 197-202.

  21. Alessio E., Iengo E., Zorzet S., Bergamo A., Coluccia M., Boccarelli A., Sava G., "Antimestatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[[trans-RuCl4(ME2SO)]2(mu-L)] (L=ditopic, non-chelating aromatic N-Ligand). A preliminary investigation". Journal of inorganic biochemistry, 2000, Vol. 79, pp. 173-177.

  22. Pacor S., Vadori M., Vita F., Bacac M., Soranzo M. C., Zabucchi G., Sava G., "Isolation of a murine metastatic cell line and preliminary test of sensitivity to the antimetastasis agent NAMI-A.". Anticancer research, 2001, Vol. 21, pp. 2523-2530.

  23. Pacor S., Bacac M., Vadori M., Vismara S., Manfrin A., Sava G., "Immunostimulating effects of oral lysozyme on a vaccination treatment with Vibrio anguillarum.". Farmacia e terapia, 2001, Vol. XVIII, pp. 51-55.

  24. Bergamo A., Zorzet S., Cocchietto M., Carotenuto M. E., Magnarin M., Sava G., "Tumour cell uptake G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells.". Anticancer research, 2001, Vol. 21, pp. 1893-1898.

  25. Zorzet S., Sorc A., Casarsa C., Cocchietto M., Sava G., "Pharmacological effects of the ruthenium complex NAMI-A given orally to CBA mice with MCa mammary carcinoma.". Metal based drugs, 2001, Vol. 8, pp. 1-8.

  26. Stecchini M. L., Del Torre M., Donda S., Maltini E., Pacor S., "Influence of agar content on the growth parameters of Bacillus cereus.". International journal of food microbiology, 2001, Vol. 64, pp. 81-88.

  27. Crul M., Van Den Bongard H. J., Tibben M. M., Van Tellingen O., Sava G., Schellens J. H., Beijnen J. H., "Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry.". Fresenius journal of analytical chemistry, 2001, Vol. 369, pp. 442-445.

  28. Rossin R., Zorzet S., Zanella A., Turrin C., Sava G., Moschini G., Perbellini A., Mazzi U., "In vivo biodistribution studies on hyaluronan butyrate by means of 99mTc direct labelling and YAP camera.". In Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine, Nicolini M., Mazzi U. (a cura di), Padova: SGEditoriali, 2002, pp. 689-693.

  29. Pintus G., Tadolini B., Posadino A., Sanna B., Debidda M., Bennardini F., Sava G., Ventura C., "Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation.". European journal of biochemistry, 2002, Vol. 269, n. 23, pp. 5861-5870.

  30. Bouma M., Nuijen B., Jansen M., Sava G., Bult A., Beijnen J. H., "Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A.". Journal of pharmaceutical and biomedical analysis, 2002, Vol. 30, n. 4, pp. 1287-1296.

  31. Bouma M., Nuijen B., Sava G., Perbellini A., Flaibani A., Van Steenbergen M., Talsma H., Ketten-van Den Bosch J., Bult A., Beijnen J. H., "Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.". International journal of pharmaceutics, 2002, Vol. 248, n. 1-2, pp. 247-259.

  32. Bouma M., Nuijen B., Jansen M., Sava G., Bult A., Beijnen J. H., "A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.". International journal of pharmaceutics, 2002, Vol. 248, n. 1-2, pp. 239-246.

  33. Sanna B., Debidda M., Pintus G., Tadolini B., Posadino A., Bennardini F., Sava G., Ventura C., "The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway.". Archives of biochemistry and biophysics, 2002, Vol. 403, n. 2, pp. 209-218.

  34. Pacor S., Giangaspero A., Bacac M., Sava G., Tossi A., "Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic use.". Journal of antimicrobial chemotherapy, 2002, Vol. 50, n. 3, pp. 339-348.

  35. Vacca A., Bruno M., Boccarelli A., Coluccia M., Ribatti D., Bergamo A., Garbisa S., Sartor L., Sava G., "Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A.". British journal of cancer, 2002, Vol. 86, n. 6, pp. 993-998.

  36. Cocchietto M., Skert N., Nimis P. L., Sava G., "A review on usnic acid, an interesting natural compound.". Naturwissenschaften, 2002, Vol. 89, n. 4, pp. 137-146.

  37. Bergamo A., Gava B., Alessio E., Mestroni G., Serli B., Cocchietto M., Zorzet S., Sava G., "Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity". International journal of oncology, 2002, Vol. 21, pp. 1331-1338.

  38. Frausin F., Cocchietto M., Bergamo A., Scarcia V., Furlani A., Sava G., "Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells.". Cancer chemotherapy and pharmacology, 2002, Vol. 50, n. 5, pp. 405-411.

  39. Sava G., Bergamo A., Zorzet S., Gava B., Casarsa C., Cocchietto M., Furlani A., Scarcia V., Serli B., Iengo E., Alessio E., Mestroni G., "Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.". European journal of cancer, 2002, Vol. 38, n. 3, pp. 427-435.

  40. Bergamo A., Stocco G., Gava B., Cocchietto M., Alessio E., Serli B., Iengo E., Sava G., "Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines.". Journal of pharmacology and experimental therapeutics, 2003, Vol. 305, n. 2, pp. 725-732.

  41. Akbayeva D., Gonsalvi L., Oberhauser W., Peruzzini M., Vizza F., Bruggeller P., Romerosa A., Sava G., Romerosa A., Bergamo A., "Synthesis, catalytic properties and biological activity of new water soluble ruthenium cyclopentadienyl PTA complexes [(C5R5)RuCl(PTA)2] (R = H, Me; PTA = 1,3,5-triaza-7-phosphaadamantane).". Chemical communications, 2003, Vol. 21, n. 2, pp. 264-265.

  42. Bergamo A., Stocco G., Gava B., Cocchietto M., Alessio E., Serli B., Iengo E., Sava G., "Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines". Journal of pharmacology and experimental therapeutics, 2003, Vol. 305, pp. 725-732.

  43. Cocchietto M., Zorzet S., Sorc A., Sava G., "Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration.". Investigational new drugs, 2003, Vol. 21, n. 1, pp. 55-62.

  44. Morbidelli L., Donnini S., Filippi S., Messori L., Piccioli F., Orioli P., Sava G., Ziche M., "Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers.". British journal of cancer, 2003, Vol. 88, n. 9, pp. 1484-1491.

  45. Sava G., Zorzet S., Turrin C., Vita F., Soranzo M. R., Zabucchi G., Cocchietto M., Bergamo A., Digiovine S., Pezzoni G., Sartor L., Garbisa S., "Dual Action of NAMI-A in Inhibition of Solid Tumor Metastasis: Selective Targeting of Metastatic Cells and Binding to Collagen.". Clinical cancer research, 2003, Vol. 9, n. 5, pp. 1898-1905.

  46. Messori L., Marcon G., Orioli P., Fontani M., Zanello P., Bergamo A., Sava G., Mura P., "Molecular structure, solution chemistry and biological properties of the novel [ImH][trans-IrCl(4)(Im)(DMSO)], (I) and of the orange form of [(DMSO)(2)H][trans-IrCl(4)(DMSO)(2)], (II), complexes.". Journal of inorganic biochemistry, 2003, Vol. 95, n. 1, pp. 37-46.

  47. Bouma M., Nuijen B., Jansen M., Sava G., Picotti F., Flaibani A., Bult A., Beijnen J. H., "Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A.". Journal of pharmaceutical and biomedical analysis, 2003, Vol. 31, n. 2, pp. 215-228.

  48. Bergamo A., Stocco G., Casarsa C., Cocchietto M., Alessio E., Serli B., Zorzet S., Sava G., "Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion.". International journal of oncology, 2004, Vol. 24, n. 2, pp. 373-379.

  49. Ferrari M., Bisceglie F., Pelosi G., Tarasconi P., Albertini R., Dall\\\'Aglio P., Pinelli S., Bergamo A., Sava G., "Synthesis, characterization and biological activity of copper complexes with pyridoxal thiosemicarbazone derivatives. X-ray crystal structure of three dimeric complexes.". Journal of inorganic biochemistry, 2004, Vol. 98, n. 2, pp. 301-312.

  50. Turel I., Pecanac M., Golobic A., Alessio E., Serli B., Bergamo A., Sava G., "Solution, solid state and biological characterization of ruthenium(III)-DMSO complexes with purine base derivatives.". Journal of inorganic biochemistry, 2004, Vol. 98, n. 2, pp. 393-401.

  51. Bacac M., Hotze A., Schilden K., Haasnoot J., Pacor S., Alessio E., Sava G., Reedijk J., "The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.". Journal of inorganic biochemistry, 2004, Vol. 98, n. 2, pp. 402-412.

Ugo Traversa

  1. A.M. Rosati, E. Guarnieri, E. Avignone., E. Cherubini, A. Cattaneo, U. Traversa.  Increased density of M1 receptors in the hippocampus of juvenile rats chronically deprived of NGF. Brain Res. 815/2, 185-191, 1999

  2. L. Candussio, G. Decorti, E. Crivellato, A.M. Rosati, U. Traversa, F. Bartoli Klugmann.  Transport of doxorubicin in mast cell granules and the effect of the calcium antagonist verapamil. Anticancer Res. 19, 1101-1108, 1999

  3. U. Traversa, Rosati A.M.  Mechanisms of inhibitory effects of zinc and cadmium ions on agonist binding to adenosine A1 receptors in rat brain. Biochem. Pharmacol. 58, 623-632,1999

  4. A.Poli, R. Lucchi, S. Notari, G. Zampacavallo, U. Traversa.  Pharmacological characterization of adenosine A1 receptors and its functional role in brown trout (Salmo Trutta) brain. Brain Res., 837, 46-54, 1999

  5. P. Di Iorio, F. Caciagli, P. Giuliani, P. Ballarin, R. Ciccarelli, O. Sperling, E. Zoref-Shani, L. Benowitz, U. Traversa, T. Florio, I. D’Alimonte, C. M. Andrew, C. E. Crocker, E. S. Werstiuk, P. J. Middlemiss, M. P. Rathbone. Purine nucleosides protect injured neurons and stimulate neuronal regeneration by intracellular and memebrane receptor-mediated mechanisms. Drug. Dev. Res. 52/1, , 303-313, 2001 

  6. Poli, Di Iorio, Beraudi, Notari, Zaccanti, Villani, Traversa.The calcium-dependent [3H] acetylcholine release from synaptosomes of brown trout (Salmo Trutta) optic tectum is inhibited by adenosine A1 receptors.Effects of enucleation on A1 receptor density and cholinergic markers.Brain Research. 892,78/85,2001

  7. U. Traversa, G. Bombi, P.Di Iorio, R. Ciccarelli, E.S. Werstiuk, M.P. Rathbone. Specific 3H-guanosine binding sites in rat brain membranes. Br. J. Pharmacol. 135, 969-976, (2002)

  8. P. Di Iorio, S. Kleywegt, R. Ciccarelli, .U Traversa, C.M. Andrew., C.E. Crocker, E.S. Werstiuk, M.P. Rathbone. Mechanisms of apoptosis induced by purine nucleosides in astrocytes. Glia 38, 179-190, 2002

  9. Ballerini P., Di Iorio P., Ciccarelli R., Nargi E., D'Alimonte I., Traversa U., Rathbone M. P., Caciagli F., "Glial cells express multiple ATP binding cassette proteins which are involved in ATP release.". Neuroreport, 2002, Vol. 13, n. 14, pp. 1789-1792.

  10. Beraudi A., Traversa U., Villani L., Sekino Y., Nagy J., Poli A., "Distribution and expression of A1 adenosine receptors, adenosine deaminase and adenosine deaminase-binding protein (CD26) in goldfish brain.". Neurochemistry international, 2003, Vol. 42, n. 6, pp. 455-464.

  11. Traversa U., Bombi G., Camaioni E., Macchiarulo A., Costantino G., Palmieri C., Caciagli F., Pellicciari R., "Rat brain guanosine binding site. Biological studies and pseudo-receptor construction.". Bioorganic and medicinal chemistry letters, 2004, Vol. 13, n. 24, pp. 4345-4350.

Sonia Zorzet

Vedi anche pubblicazioni in collaborazione con Tullio Giraldi

PROF. ENRICO TONIN, DR. ELENA BANFI, LUCILLA DOLZANI, MARISA TAMARO

  1. Lagatolla C., Dolzani L. and Monti-Bragadin C. 1998. Characterization of the phenotype conferred by two different rpsL alleles coding for streptomycin dependence. Microbiologica, 21:105-111.

  2. Lagatolla C., Lavenia A., Tonin E., Monti-Bragadin C. and Dolzani L. 1998. Characterization of oligonucleotide probes for the identification of Acinetobacter spp., A. baumannii and Acinetobacter genomic species   Res. Microbiol., 149:557-566.

  3. Lagatolla C., Dolzani L., Granzotto M. and Monti-Bragadin C. 1998. Genotoxic activity of 4,4’,5’-trimethylazapsoralen on plasmid DNA. Teratogen. Carcin. Mut., 18:239-248.

  4. Banfi E., M.G. Mamolo, L.Vio. . 1998.  Synthesis and antimycobacterial activity of neosynthesized 2- pyridincarboxamidrazone derivatives. Rev. Port. Pneumol, 4:3.

  5. L Dolzani, , E. Banfi, M Predominato. 1998.- Develo pment of a quantitative diagnostic procedure for Mycobacterium tuberculosis  infection.  Rev. Port. Pneumol.  4:8.

  6. Silvestri L., Monti-Bragadin C., Milanese M., Gregori D., Consales C., Gullo A. and Van Saene H.K.F. 1999. Are most ICU infections teally nosocomial? A prospective observational cohort study in mechanically ventilate patients. J. Hosp. Infect. 42:125-133.

  7. Borelli V., E. Banfi, M.G. Perrotta and G. Zabucchi. 1999. Myeloperoxidase exerts microbicidal activity against Mycobacterium tuberculosis. Infect. Immun.  67:4149-4152.

  8. Mamolo M.G., V. Falagiani, L. Vio and E. Banfi. 1999. Synthesis and antimycobacterial activity of some N1-[1-[3-aryl-1-(pyridin-2-,3-, or 4-yl)-3-oxo]propyl]-2-pyridinecarboxamidrazones. Il Farmaco 54:761-767.

  9. Tonin E. A., Dolzani L., Lagatolla C., Lavenia A., Prandin L., Tassan R. e Monti-Bragadin C. 1999. Studio della regione “spacer” presente nei geni per l’rRNA 16-23S. L’Igiene Moderna 111:1-11.

  10. Barca, B. Pani, M. Tamaro, E. Russo. 1999. Molecular interactions of ruthenium complexes in isolated mammalian nuclei and cytotoxicity on V79 cells in culture. Mutat. Res. 423:171-181.

  11. M. Sturni, R. Di Lenarda, M.Cadenaro, M.Tamaro. 1999. Mutagenicità e citotossicità di cinque cementi endodontici. Il Dentista Moderno, 8:93-105.

  12. Rossolini G.M., Riccio M.L., Cornaglia G., Pagani L., Lagatolla C., Selan L. and Fontana R. 2000. Carbapenem-resistant Pseudomonas aeruginosa with acquired bla VIM metallo-b-lactamase determinants, Italy. Emerg. Infect. Dis., 6:312-313.

  13. M.Benincasa,P. Rovere, G. Carpi, S. Gola, M. Tamaro. 2000. Influence of high pressure treatment of Brassica oleracea var. capitata on the genotoxic and antimutagenic activities in S. typhimurium. Industria Conserve, 75:35-47.

  14. Garcia R.C., E. Banfi. M.G. Pittis . 2000.  Infection of macrophage-like THP-1 cells with Mycobacterium avium results in a decrease in their ability to phpsphorylate nucleolin. Infect. Immun. 68:3121-3128.

  15. S Bosi, T DaRos, S Castellano, E. Banfi and M Prato. 2000. Antimycobacterial activity of ionic fullerene derivatives. Bioorganic Medicinal Chemistry Letters 10:1043-1045.

  16. M G Mamolo, V Falagiani, D Zampieri, L Vio and E Banfi. 2000.  Syntheisis and antimycobacterial activity of some 4H -1,2,4-triazin-one derivatives. Il Farmaco 55:590-595.

  17. Mantovanelli A, Marino M., Comi G., Vallavanti W. e Dolzani, L. (2001). Controllo microbiologico di prodotti alimentari ed attrezzature finalizzato alla verifica di sistemi HACCP e GMP. Industrie Alimentari XL:853-865.

  18. Banfi E, Mamolo MG, Zampieri D, Vio L, Monti-Bragadin C. Antimycobacterial activity of N1-(1-(3-aryl-1-(pyridin-2-3- or 4-yl)-3-oxo) propyl-2-pyridinecarboxamidrazones. Journal of Antimicrobial Chemotherapy (2001), 48:705-707.

  19. Mamolo MG, Falagiani V, Zampieri D, Vio L, Banfi E.Synthesis and antimycobacterial activity of (5- (pyridin-2-yl)-1,3,4-thiadiazol-2-ylthio)acetic acid arylidene-hydrazide derivatives. Il Farmaco (2001), 56: 587-592.

  20. Mamolo MG, Zampieri D, Falagiani V, Vio L, Banfi E. Synthesis and antimycobacterial activity of 5-aryl-1-isonicotinoyl-33-(pyridin-2-yl)-4,5-dihydro-1H-pyrazole derivatives. Il Farmaco (2001), 56: 593-599.

  21. Borelli V, Vita F, Soranzo MR, Banfi E, Zabucchi G. Ultrastructure of the interaction between mycobacterium tuberculosis- H37Rv-containing phagosomes and the lysosomal compartment in human alveolar macrophages.Exp Mol Pathol. 2002 Oct;73(2):128-34.

  22. Pastorello EA, Pravettoni V, Calamari AM, Banfi E, Robino AM. New plant-origin food allergens.Allergy. 2002;57 Suppl 72:106-10. Review.

  23. Gombac F, Riccio ML, Rossolini GM, agatolla C, Tonin E, Monti-Bragadin C, La venia A, Dolzani L. Molecular characterization of integrons in epidemiologically unrelated clinical isolates of Acinetobacter baumannii from Italian hospitals reveals a limited diversity of gene cassette arrays.Antimicrob Agents Chemother. 2002 Nov;46(11):3665-8.

  24. Lagatolla C, Skerlavaj S, Dolzani L, Tonin EA, Monti-Bragadin C, Bosco M, Rizzo R, Giglio L, Cescutti P. Microbiological characterisation of Burkholderia cepacia isolates from cystic fibrosis patients: investigation of the exopolysaccharides produced.FEMS Microbiol Lett. 2002 Mar 19;209(1):99-106.

  25. Marsich E, Zuccato P, Rizzi S, Vetere A, Tonin E, Paletti S. Helicobacter pylori expresses an autolytic enzyme: gene identification, cloning, and theoretical protein structure.J Bacteriol. 2002 Nov;184(22):6270-9.

  26. Cateni F., Zilic J., Falsone G., Scialino G., Banfi E., "New cerebrosides from Euphorbia peplis L.: antimicrobial activity evaluation.". Bioorganic and medicinal chemistry letters, 2003, Vol. 13, n. 24, pp. 4345-4350.

  27. Cescutti P., Impallomeni G., Garozzo D., Sturiale L., Herasimenka Y., Lagatolla C., Rizzo R., "Exopolysaccharides produced by a clinical strain of Burkholderia cepacia isolated from a cystic fibrosis patient.". Carbohydrate research, 2003, Vol. 338, n. 23, pp. 2687-2695.

  28. Mamolo M. G., Falagiani V., Zampieri D., Vio L., Banfi E., Scialino G., "Synthesis and antimycobacterial activity of (3,4-diaryl-3H-thiazol-2-ylidene)-hydrazide derivatives". Il farmaco, 2003, Vol. 58, n. 9, pp. 632-637.

  29. Mamolo M. G., Zampieri D., Falagiani V., Vio L., Banfi E., "Synthesis and antifungal activity of (+/-)-1-(5-aryl-3-pyridin-2-yl-4,5-dihydro-pyrazol-1-yl)-2-imidazol-1-yl-ethanone derivatives.". Il farmaco, 2003, Vol. 58, n. 4, pp. 315-322.

  30. Borelli V., Vita F., Shankar S., Soranzo M. R., Banfi E., Scialino G., Brachetta C., Zabucchi G., "Eosinophil Peroxidase Induces Surface Alteration, Killing, and Lysis of Mycobacterium tuberculosis.". Infection and immunity, 2003, Vol. 71, n. 2, pp. 605-613.

  31. Dolzani L., Rosato M., Sartori B., Banfi E., Lagatolla C., Predominato M., Fabris C., Tonin E. A., Gombac F., Monti Bragadin C., "Mycobacterium tuberculosis isolates belonging to katG gyrA group 2 are associated with clustered cases of tuberculosis in Italian patients.". Journal of medical microbiology, 2004, Vol. 53, n. pt 2, pp. 155-159.

 

PROF.MARINA CINCO:  

  1. M.G. Rittig,J.C. Jagoda, B. Wilske, R. Murgia,M. Cinco, R. Repp,G.R. Burmester, A. Krause.Coiling phagocytosis discriminates morphologically similar sprochetes and is enhanced by phorbol myristate and GM-CSF. Infect. Immun.66; 627-635. 1998.
  2. M. Cinco,D. Padovan, R. Murgia, L. Poldini, L. Frusteri, I. van de Pol, N. Verbeek de Kruif, S. Rijpkema, and M. Maroli. Rate of infection of I. ricinus ticks with Borrelia burgdorferi sensu stricto, Borrelia garinii, Borrelia afzelii and group VS 116 in an endemic focus of Lyme disease in Italy. Europ. J. of Microbiology and Infectious Diseases, 17: 90-94,1998.
  3. Tony H.S. Woo, Patel BK, Cinco M, Smythe LD,Symonds ML,Wonis MA, Dohnt MF. Real-time homogeneous assay of rapid cycle polymerase chain reaction product for identification of Leptonema illini. Anal Biochem. 15; 259(1): 112-117,1998.
  4. Rodolfo Garcia, Laura Gusmani, Rossella Murgia, Corrado Guarnaccia, Marina Cinco and Giandomenico Rottini. Elastase is the Human Neutrophil Granule Protein Responsible for the In Vitro Killing of the Lyme Disease Spirochete Borrelia Burgdorferi. Infection and Immunity, 66,4,1408-1412, 1998.
  5. Liliana Frusteri, Dario Padovan, Rossella Murgia, Livio Poldini, Michele Maroli,Marina Cinco. Studies on natural infection of Ixodes ricinus (Acarina: Ixodidae) in Italy: Report on multiple microorganisms coinfection (B.burgdorferi and Ehrlichia spp.).Alpe Adria Microbiology Journal, 7,2,123-131,1998.
  6. A.N. Alekseev,H.V. Dubinia, L.P. Antykova, Tatyana I. Dzhivanyan, S. G.T. Rijpkema, N.V. De Kruif, M. Cinco. Tick-borne borrelioses pathogen identification in Ixodes ticks (Acarina Ixodidae) collected in St. Petesburg and Kaliningrad Baltic Regions of Russia. J. of Medical Entomology, 35,2,136-142, 1998.
  7. M. Cinco .La borreliosi di Lyme. Monografia, Collana Caleidoscopio, N° 122, 1998.
  8. M. Cinco, D. Padovan, R. Murgia, L. Frusteri, M. Maroli, I. van de Pol, N. Verbeek-De Kruif, S. Rijpkema, F. Taggi. Prevalence of Borrelia burgdorferi Infection in Ixodes ricinus in Central Italy. Eur. J. Clin. Microbiol. Infect. Dis. 17: 131-136,1998.
  9. Marina Cinco, Rossella Murgia, Sandra Perticarari and Gianni Presani. Surface   receptors of neutrophils towards B.burgdorferi.  The Middle European Journal of Medicine,24: 898-901, 1998.
  10. M. Cinco, D. Padovan, R. Murgia, M. Heldtandedr and E. Olsson Engvall. Detection     of HGE agent –like Ehrlichia in Ixodes ricinus ticks in Northern Italy  by PCR. The Middle European Journal of Medicine,24: 866-870, 1998.
  11. T.H.S. Woo, B. K.C. Patel, Marina Cinco, Smythe L.D., M. Norris, M. L. Symonds,     M. F. Dohnt and Piispanen J. Identification of Leptospira biflexa  by Real timehomogeneous  Detection of rapid cycle PCR product. J. Microbiol. Methods, 35 :  23-30, 1999.
  12. Murgia R., Federico Marchetti and Marina Cinco. Comparative Bacteriostatic and Bactericidal Activity of Cefodizime on Borrelia burgdorferi  sensu lato. Antimicrobial Agents and Chemiotherapy. 43,12:  3030-3032,1999.
  13. M.Cinco, R.Murgia, M. Ruscio, F.Rapagna and S.LaMalfa.IgM and IgG significant  reactivity      to Borrelia garinii and Borrelia afzelii  among Italian patients affected by  early Lyme borreliosis.Alpe Adria Journal of Clinical Microbiology,      8,1: 63-73,1999.
  14. Cinco M. Ruscio m.and F.Rapagna . Expression of DbpA DbpB antigens among European strains of Borrelia burgdorferi sensu lato and in the immune response of LB patient sera. FEMS Microbiology Letters ,1:183,111-114, 2000.
  15. Liang FT, Aberer E, Cinco M,  Gern L,  Lobet Y, Ruscio M, Voet PE, Weynants ve, and M. Philipp. Antigenic conservation of an Immunodominant Invariable region of the VLsE lipoprotein among European Pathogenic genospecies of Borrelia burgdorferi. Journal of Infectious Diseases, 182: 1455-1462.2000.
  16. Ciceroni L., Stepan E., Pinto A., Pizzocaro P., Dettori G., Franzin L., Lupidi R., Manera A., Ioli A., Marcuccio L., Grillo R., Ciarrocchi S., Marina Cinco. Epidemiological trend of human leptospirosis in Italy between 1994 and 1996. Europ. J. Epidemiology,16: 79-86, 2000.
  17. Cinco M., Panfili E.,  Presani G., Perticarari S. Interaction with Borrelia burgdorferi causes increased expression of the CR3 integrin and increasing binding affinity to fibronectin via CR3. JMMB,2(4): 575-579 2000.
  18. Murgia R., Piazzetta C., and M. Cinco. Induction and RpoS role in cystic forms development from B.burgdorferi. The Middle European Journal of Medicine, 2000.
  19. Gruntar I, Malovrh T, Murgia R, Cinco M. Conversion of Borrelia garinii cystic forms to motile spirochetes in vivo. APMIS. May;109(5):383-8, 2001.
  20. Cinco M, Cini B,  Murgia R,  Presani G,Prodan M, and Perticarari S. Evidence of Involvement of the Mannose Receptor in Adhesion of Borrelia burgdorferi to Monocyte/Macrophages Infect. Immun. 69,4,2743-2747, 2001.
  21. Ciceroni L, Ciarrocchi S, Cervo A., Mondardini V, Guzzo F, Caruso G., Murgia R.and Cinco M.. Isolation and characterization of Borrelia burgdorferi sensu lato strains in an Area of Italy Endemic for Lyme Borreliosis. J. Clin. Microbiology, 39 (6), 2254-60, 2001.
  22.   Murgia R & M. Cinco.Sensitivity of Borrelia burgdoferi and Leptospira to quinupristin-dalfopristin (Synercid ®) in vitro. New Microbiol. 24(2):193-, 2001.
  23. M. Cinco. Borrelia burgdorferi genospecies in humans and ticks in the Alpe Adria region. Acta Dermatovenerologica ,10,4,131-133, 2001.
  24. Altobelli A., Feoli E. Napoletano R.  and  Cinco M. Remote Sensing/GIS technique for risk assessment of Borrelia burgdorferi infection. The Geomatics Workbook,2, autumn 2001.
  25. Pausa M, Pellis V, Cinco M , Giulianini P.G., Presani G., Perticarari S.. Serum resistant strains of Borrelia burgdorferi evade complement -mediated killing by expressing a CD59-like complement inhibitory molecule.J. Immunol. 2002.  
  26. Sembri V., Marangoni, A. Giacani L,  Gennaro R., Murgia R.,Cevenini R., Cinco M.  Comparative in vitro activity of five cathelicidin synthetic derived peptides against Leptospires, Borrelia and Treponema pallidum. J.Antimicrob. Chemother. 50 (6), 895-902  2002
  27. Cinco M, Cini B,  Perticarari  S,and Presani G.. Leptospira interrogans binds to the CR3 receptor on mammalian cells. Microb. Pathog. 33(6) 299-305 2002
  28. Murgia R. Piazzetta C, Cinco M. Cystic forms of Borrelia bugdorferi sensu lato: induction, development, and role of RpoS. Wien Klin Wochenschr. 114(13-14) 574-9 2002
  29. Murgia R, Garcia R, Cinco M.Leptospires are killed in vitro by both oxygen-dependent and indipendent reactions.Infect. Immun. 70(12) 7172-5 2002.
  30. Plaza A., Cinco M., Tubaro A., Pizza C., Piacente S., "New triterpene glycosides from the stems of Anomospermum grandifolium". Journal of natural products, 2003, Vol. 66, n. 12, pp. 1606-1610.
  31. Pausa M., Pellis V., Cinco M., Giulianini P. G., Presani G., Perticarari S., Murgia R., Tedesco F., "Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule". Journal of immunology, 2003, Vol. 170, n. 6, pp. 3214-3222.
  32. Ruscio M., Cinco M., "Human granulocytic ehrlichiosis in Italy: first report on two confirmed cases.". Annals of the New York academy of sciences, 2003, Vol. 990, pp. 350-352.
  33. Mannelli A., Boggiatto G., Grego E., Cinco M., Murgia R., Stefanelli S., De Meneghi D., Rosati S., "Acarological risk of exposure to agents of tick-borne zoonoses in the first recognized Italian focus of Lyme borreliosis.". Epidemiology and infection, 2003, Vol. 131, n. 3, pp. 1139-1147.
  34. Murgia R., Cinco M., "Induction of cystic forms by different stress conditions in Borrelia burgdorferi.". APMIS, 2004, Vol. 112, n. 1, pp. 57-62.

     

Home, Dipartimento di Scienze Biomediche